AbbVie (NYSE:ABBV) Trading Up 1.9% – Here’s What Happened

Shares of AbbVie Inc. (NYSE:ABBV) rose 1.9% during mid-day trading on Thursday . The company traded as high as $211.45 and last traded at $211.1160. Approximately 4,545,781 shares traded hands during trading, a decline of 39% from the average daily volume of 7,391,874 shares. The stock had previously closed at $207.18.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics (an AbbVie company) will present 21 evidence-based e-posters at the Aesthetic & Anti-Aging Medicine World Congress (AMWC), highlighting clinical and real‑world data that support its aesthetics leadership and could bolster the JUVÉDERM franchise and procedure demand. Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)
• Positive Sentiment: Allergan is promoting a new “Undetectable” era for hyaluronic acid injectables with the JUVÉDERM portfolio at AMWC — product marketing and clinical messaging that can support premium pricing and market share in aesthetics. Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
• Positive Sentiment: AbbVie is rolling out major consumer/brand initiatives — including an official MLB partnership and related sponsorships — which can raise awareness for its consumer-facing and specialty franchises. (Marketing reach helps long‑term demand for products tied to brand recognition.) How AbbVie’s official partnership with MLB will unfold over the course of the season
• Neutral Sentiment: Erste Group slightly raised its FY2027 EPS model for AbbVie, a modest analyst backing that supports earnings strength but is not a major upgrade driver on its own.
• Neutral Sentiment: Media and research outlets are highlighting AbbVie’s expansion into psychiatry after the 2025 acquisition of bretisilocin (a Phase 2 psychedelic candidate). This boosts long‑term pipeline optionality but remains early‑stage and uncertain. Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026?
• Neutral Sentiment: Industry/market coverage and interest pieces (Zacks, valuation roundups) are increasing visibility for ABBV, which can amplify trading volume on both buys and sells.
• Negative Sentiment: Recent price weakness (declines over the past week/month) and renewed questions about valuation have pressured sentiment; valuation commentary may keep some investors cautious in the near term. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

Wall Street Analysts Forecast Growth

ABBV has been the topic of several analyst reports. Morgan Stanley lifted their target price on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Berenberg Bank set a $275.00 price objective on AbbVie in a research note on Tuesday, January 20th. Barclays began coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective on the stock. Piper Sandler boosted their price objective on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and increased their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Trading Up 1.9%

The company has a 50 day simple moving average of $222.17 and a two-hundred day simple moving average of $224.62. The firm has a market capitalization of $373.29 billion, a P/E ratio of 89.46, a P/E/G ratio of 0.71 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter last year, the business posted $2.16 earnings per share. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s payout ratio is presently 293.22%.

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is owned by corporate insiders.

Institutional Trading of AbbVie

A number of large investors have recently added to or reduced their stakes in the company. J. Derek Lewis & Associates Inc. bought a new stake in AbbVie in the fourth quarter worth $4,173,000. Purpose Unlimited Inc. bought a new position in AbbVie during the fourth quarter valued at $172,000. Stance Capital LLC lifted its position in AbbVie by 1.4% during the fourth quarter. Stance Capital LLC now owns 6,240 shares of the company’s stock valued at $1,426,000 after purchasing an additional 86 shares during the last quarter. Cornerstone Planning LLC purchased a new position in shares of AbbVie in the 4th quarter worth $3,421,000. Finally, Rockefeller Capital Management L.P. grew its stake in shares of AbbVie by 10.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 883,644 shares of the company’s stock worth $201,904,000 after buying an additional 81,375 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.